NLE Hematologic Nursing — Bleeding, Clotting and Hematologic MalignanciesDetailed Explanation

Normal Hemostasis and Platelet Function

Hemostasis is the body's natural process of stopping bleeding. Think of it as a three-step emergency response system. First, when a blood vessel is injured, it immediately constricts (vasoconstriction) to slow blood flow. Second, platelets rush to the site and clump together to form a temporary plug — this is called primary hemostasis. Third, the coagulation cascade is activated, producing a fibrin mesh that reinforces the platelet plug into a stable clot — this is secondary hemostasis. Normal platelet count is 150,000–400,000 per microliter (µL) of blood. Understanding platelet count thresholds is critical for NLE: ABOVE 50,000/µL — generally safe for most activities; BELOW 50,000/µL — risk of bleeding with trauma or surgery; BELOW 20,000/µL — risk of SPONTANEOUS bleeding (bleeding without any injury); BELOW 10,000/µL — risk of SEVERE, LIFE-THREATENING, SPONTANEOUS hemorrhage, including intracranial bleeding. The nurse must memorize these thresholds because NLE frequently tests at what platelet level specific nursing interventions are required.

Thrombocytopenia and Immune Thrombocytopenic Purpura (ITP)

Thrombocytopenia means the platelet count is BELOW 150,000/µL. It can result from three main mechanisms: (1) DECREASED PRODUCTION — the bone marrow is not making enough platelets (causes: chemotherapy, aplastic anemia, marrow infiltration by cancer, nutritional deficiencies); (2) INCREASED DESTRUCTION — platelets are being destroyed faster than they are made (causes: immune attack as in ITP, DIC, heparin-induced thrombocytopenia/HIT); (3) SEQUESTRATION — platelets are trapped in an enlarged spleen (splenomegaly), so they are not circulating. IMMUNE THROMBOCYTOPENIC PURPURA (ITP) is the most important type for NLE purposes. In ITP, the immune system makes autoantibodies (IgG) that coat the patient's own platelets. The spleen recognizes these coated platelets as foreign and destroys them. The bone marrow tries to compensate by making more megakaryocytes (platelet precursors), so the marrow actually shows INCREASED megakaryocytes — an important diagnostic clue. Clinical presentation of ITP: petechiae (pinpoint red spots, usually on the lower extremities and mucosal surfaces), purpura (larger purple patches), ecchymoses (bruises), gum bleeding, nosebleeds (epistaxis), and in women, heavy menstrual periods (menorrhagia). Important: ITP typically does NOT cause organ failure — it primarily causes bleeding manifestations. HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) is a special, dangerous form where heparin triggers immune antibodies that activate platelets — paradoxically causing BOTH a low platelet count AND dangerous CLOTTING (thrombosis). The key nursing action: STOP ALL HEPARIN IMMEDIATELY, including heparin flushes. Use alternative anticoagulants (argatroban, bivalirudin). Treatment of ITP: (1) Corticosteroids (prednisone) — suppress the immune attack, first-line treatment; (2) IV Immunoglobulin (IVIG) — rapidly raises platelet count by blocking spleen Fc receptors, used for acute bleeding or before surgery; (3) Anti-D immunoglobulin — used in Rh-positive patients, similar mechanism to IVIG; (4) Thrombopoietin receptor agonists (romiplostim, eltrombopag) — stimulate platelet production; (5) Splenectomy — removes the organ destroying the platelets, used for refractory (treatment-resistant) ITP.

Disseminated Intravascular Coagulation (DIC)

DIC is one of the most complex and deadly hematologic emergencies. The key to understanding DIC is this: it is a SECONDARY disorder — it is always caused by something else. Think of DIC as a two-phase catastrophe. PHASE 1 (CLOTTING): A trigger activates the clotting cascade throughout the ENTIRE body simultaneously. Tiny blood clots (microthrombi) form in blood vessels all over the body. These microthrombi block blood flow to organs, causing ischemia (oxygen starvation). PHASE 2 (BLEEDING): All this widespread clotting uses up (consumes) the body's platelets and clotting factors faster than they can be replaced. Now the patient has almost no ability to form clots — and paradoxically BLEEDS uncontrollably from everywhere. This is why DIC is sometimes called 'consumptive coagulopathy' — the clotting process consumes itself into bleeding. TRIGGERS OF DIC (memorize these — NLE frequently tests them): SEPSIS is the MOST COMMON trigger (gram-negative bacteria release endotoxins that activate clotting); Obstetric emergencies (placental abruption, amniotic fluid embolism, eclampsia); Massive trauma or burns; Malignancy (especially AML-M3/promyelocytic leukemia); ABO-incompatible blood transfusion reaction; Snakebite (venom activates clotting). CLINICAL MANIFESTATIONS — the patient has signs of BOTH clotting AND bleeding simultaneously: Clotting signs: organ failure (renal failure, respiratory failure), acral cyanosis (blue fingertips/toes from microvascular clots), gangrene; Bleeding signs: oozing from IV sites and catheter insertion points (classic early sign), petechiae, purpura, ecchymosis, hematuria, GI bleeding, hemoptysis. LABORATORY FINDINGS in DIC (the most NLE-tested aspect): LOW platelets (consumed), LOW fibrinogen (consumed), PROLONGED PT (prolonged coagulation time), PROLONGED aPTT (prolonged coagulation time), ELEVATED D-dimer (clot breakdown products — the most specific indicator), ELEVATED fibrin degradation products (FDPs) or fibrin split products. The pattern: LOW-LOW-HIGH is the key memory tool: LOW platelets + LOW fibrinogen + HIGH D-dimer. MANAGEMENT: (1) Treat the UNDERLYING CAUSE — this is the ONLY definitive treatment. Stop sepsis with antibiotics, deliver the baby in obstetric emergencies, etc. (2) Replace consumed blood components: Fresh Frozen Plasma (FFP) replaces all clotting factors; Cryoprecipitate replaces fibrinogen and factor VIII; Platelet transfusion replaces platelets. (3) Heparin is controversial — sometimes used when thrombosis dominates to prevent more clots from forming, but this is a physician decision. NURSING PRIORITIES: Monitor for both bleeding (vital signs, urine output, skin) and clotting (assess extremity perfusion, organ function); Protect skin and mucous membranes; Use only necessary invasive procedures; Apply pressure to all puncture sites; Support oxygenation; Accurate intake and output monitoring.

Hemophilia

Hemophilia is an inherited bleeding disorder caused by a deficiency of a specific clotting factor. Because the gene is located on the X chromosome (X-linked recessive), it primarily affects MALES, while FEMALES are typically carriers (they have one affected X and one normal X chromosome, so they usually do not bleed but can pass the gene to their children). There are two main types: HEMOPHILIA A — deficiency of FACTOR VIII (8). This is the MOST COMMON form, accounting for about 80% of cases. HEMOPHILIA B (Christmas disease) — deficiency of FACTOR IX (9). Both factors are part of the INTRINSIC pathway of the coagulation cascade. LABORATORY FINDINGS: Prolonged aPTT (activated partial thromboplastin time) — because the intrinsic pathway is affected; NORMAL PT (prothrombin time) — the extrinsic pathway is intact; NORMAL platelet count — platelets are normal in number and function; NORMAL bleeding time — the primary platelet plug forms normally, but the secondary fibrin clot is defective. This lab pattern (isolated prolonged aPTT with everything else normal) is the diagnostic key. CLINICAL MANIFESTATIONS: Prolonged bleeding after even minor injuries, dental procedures, or surgery; HEMARTHROSIS — bleeding INTO JOINTS (knees, elbows, ankles are most common). This is the hallmark of hemophilia. Blood in a joint causes pain, swelling, warmth, and limited range of motion. Repeated hemarthroses cause chronic joint damage (hemophilic arthropathy) and deformity over time; Deep muscle hematomas; Spontaneous bruising; In severe cases, intracranial hemorrhage (rare but life-threatening). SEVERITY is classified by factor level: Severe (<1% factor activity) — spontaneous bleeding; Moderate (1–5%) — bleeding with minor trauma; Mild (5–40%) — bleeding only with significant trauma or surgery. MANAGEMENT: REPLACE THE MISSING FACTOR — the cornerstone of treatment: Factor VIII concentrate for hemophilia A; Factor IX concentrate for hemophilia B. Give at the FIRST SIGN OF BLEEDING — do not wait for it to worsen. Also given PROPHYLACTICALLY before surgery, dental procedures, or invasive tests. DESMOPRESSIN (DDAVP) — a synthetic hormone that temporarily raises factor VIII levels by releasing it from storage sites (von Willebrand factor carries factor VIII). Used ONLY for MILD HEMOPHILIA A — it does not work for hemophilia B or severe hemophilia A. For acute joint bleeds (hemarthrosis), apply RICE: REST (immobilize the joint), ICE (cold pack — not directly on skin), COMPRESSION, ELEVATION. Apply firm PRESSURE for external bleeds. AVOID: aspirin, NSAIDs (inhibit platelet function), IM injections (cause deep hematomas), invasive procedures without factor replacement cover. NURSING TEACHING: Patients and families should be taught factor self-administration at home (a major quality-of-life advancement). Medic-Alert bracelet is essential. Encourage swimming and non-contact activities; avoid contact sports. Genetic counseling for carrier females.

Leukemia

Leukemia is a cancer of the blood and bone marrow characterized by the uncontrolled proliferation of immature, abnormal white blood cells called BLASTS. These blast cells crowd out normal blood cell production in the bone marrow, resulting in the classic TRIAD of leukemia — which reflects BONE MARROW FAILURE: (1) ANEMIA (from decreased red blood cell production) — manifests as fatigue, pallor, dyspnea on exertion, tachycardia; (2) NEUTROPENIA (from decreased production of functional neutrophils) — manifests as recurrent severe infections; INFECTION IS THE LEADING CAUSE OF DEATH IN LEUKEMIA; (3) THROMBOCYTOPENIA (from decreased platelet production) — manifests as bleeding, petechiae, bruising. CLASSIFICATION: Leukemia is classified by two criteria — (A) cell line involved and (B) disease course: ACUTE vs CHRONIC. Acute = blasts accumulate rapidly, aggressive, requires immediate treatment. Chronic = more mature cells, slower progression. FOUR MAIN TYPES: Acute Lymphocytic Leukemia (ALL) — most common leukemia in CHILDREN (peak age 2–5 years); involves lymphoid progenitors; generally GOOD prognosis with treatment (up to 90% remission in children); Acute Myelogenous Leukemia (AML) — most common acute leukemia in ADULTS; involves myeloid progenitors; harder to treat, worse prognosis than ALL; AML-M3 (promyelocytic) is associated with DIC; Chronic Lymphocytic Leukemia (CLL) — most common chronic leukemia; typically in older adults (>60 years); often indolent (slow-growing), may not need immediate treatment; Chronic Myelogenous Leukemia (CML) — associated with the PHILADELPHIA CHROMOSOME (translocation of chromosomes 9 and 22, creating BCR-ABL gene); treated with TYROSINE KINASE INHIBITORS such as imatinib (Gleevec), which target the abnormal protein produced by this gene; often progresses to acute leukemia (blast crisis) if untreated. DIAGNOSIS: Complete Blood Count (CBC) — may show abnormally high, low, or normal WBC with blasts on peripheral smear; BONE MARROW BIOPSY is CONFIRMATORY — shows >20% blasts (AML) or >25% blasts (ALL) in the marrow. TREATMENT: Chemotherapy is the mainstay. Three phases for ALL: INDUCTION — achieve remission (destroy as many leukemic cells as possible); CONSOLIDATION — destroy remaining leukemic cells; MAINTENANCE — low-dose chemotherapy to prevent relapse. AML uses induction ('7+3' regimen: cytarabine for 7 days + anthracycline for 3 days) and consolidation. HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) — used for relapsed or high-risk cases; involves destroying the patient's bone marrow and replacing it with donor marrow. CML: Imatinib (Gleevec) is a targeted oral therapy that transformed CML from a fatal to a manageable disease. NURSING PRIORITIES: (1) INFECTION PREVENTION — highest priority (neutropenia → sepsis is the #1 killer); Protective/neutropenic precautions: private room, mask, strict hand hygiene, avoid fresh flowers/raw fruits/crowded places; Monitor absolute neutrophil count (ANC) — ANC <500/µL = severe neutropenic risk; Treat fever in neutropenic patients as MEDICAL EMERGENCY (febrile neutropenia = infection until proven otherwise, empiric broad-spectrum antibiotics immediately); (2) BLEEDING PRECAUTIONS for thrombocytopenia; (3) Manage chemotherapy effects: nausea/vomiting (antiemetics), mucositis (oral care), alopecia (emotional support), TUMOR LYSIS SYNDROME (complication of rapid cell kill — hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia — treat with IV hydration, allopurinol, rasburicase).

Lymphoma: Hodgkin vs. Non-Hodgkin

Lymphomas are cancers of the LYMPHATIC SYSTEM — specifically the lymphocytes (B cells and T cells) that reside in lymph nodes, the spleen, and other lymphoid tissues. The hallmark presentation is PAINLESS LYMPHADENOPATHY — enlarged lymph nodes that do not hurt (unlike reactive/infected nodes which are usually tender). HODGKIN LYMPHOMA (HL): Characterized by the presence of REED-STERNBERG CELLS on biopsy — these are giant, abnormal B cells with large, prominent nuclei that look like 'owl eyes' under the microscope. This cell is PATHOGNOMONIC (diagnostic) of Hodgkin lymphoma. Key features: Usually begins in a SINGLE lymph node region (most commonly the CERVICAL — neck — nodes); Spreads in an ORDERLY, CONTIGUOUS fashion — from one node group to the adjacent group (like stepping stones); BIMODAL AGE DISTRIBUTION — peaks in young adults (15–35 years) and again in adults over 55; Generally GOOD PROGNOSIS, especially when caught early (Stage I–II disease has >90% cure rate with treatment); Highly curable with chemotherapy (ABVD regimen: Adriamycin, Bleomycin, Vinblastine, Dacarbazine) and/or radiation. NON-HODGKIN LYMPHOMA (NHL): A diverse group of lymphomas WITHOUT Reed-Sternberg cells. Key features: More COMMON than Hodgkin lymphoma; Typically presents with MULTIPLE, WIDESPREAD lymph node involvement at diagnosis; UNPREDICTABLE spread pattern — does not follow orderly contiguous spread; More common in OLDER adults and those who are immunocompromised (HIV, organ transplant recipients); Prognosis is VARIABLE — depends on subtype (some indolent subtypes have long survival; aggressive subtypes like Burkitt's lymphoma or diffuse large B-cell lymphoma require urgent treatment); Treatment includes chemotherapy, immunotherapy (Rituximab — anti-CD20 monoclonal antibody, targets B cells), and stem cell transplant. STAGING (Ann Arbor System — applies to both): Stage I — one lymph node region; Stage II — two or more node regions on SAME side of diaphragm; Stage III — node regions on BOTH sides of diaphragm; Stage IV — disseminated disease (bone marrow, liver, lung involvement). 'B SYMPTOMS' — present in BOTH types and indicate more advanced, systemic disease, associated with WORSE PROGNOSIS: Fever (unexplained, recurrent, >38°C); Drenching Night Sweats (patient wakes up soaked); Unexplained Weight Loss (>10% body weight in 6 months). Stages are classified as 'A' (no B symptoms) or 'B' (B symptoms present) — e.g., Stage IIIB means disease on both sides of diaphragm WITH systemic symptoms. NURSING CARE: Monitor for infection (immunosuppression from both disease and treatment); Provide radiation safety teaching (if radiation is part of treatment — skin care, fatigue management, avoid sun exposure to irradiated skin); Teach about late effects of treatment: secondary cancers (especially after chest radiation for HL — breast cancer, lung cancer), hypothyroidism, cardiac toxicity from anthracyclines; Emotional support — many HL patients are young adults facing fertility concerns from chemotherapy.

Multiple Myeloma

Multiple myeloma is a cancer of PLASMA CELLS — the mature B lymphocytes responsible for producing antibodies (immunoglobulins). In myeloma, abnormal plasma cells multiply uncontrollably in the BONE MARROW and produce a non-functional, abnormal immunoglobulin called M PROTEIN (paraprotein or monoclonal protein). Because these malignant plasma cells crowd the bone marrow, they interfere with normal blood cell production. The consequences of myeloma are best remembered with the mnemonic CRAB: C — CALCIUM elevated (Hypercalcemia): Myeloma cells activate osteoclasts (bone-destroying cells), breaking down bone. This releases calcium into the bloodstream. Signs: nausea, vomiting, confusion, constipation, polyuria, lethargy (remember: 'Bones, Groans, Moans, and Psychic Overtones' for hypercalcemia symptoms). R — RENAL FAILURE: Light chain proteins (Bence Jones protein) filtered by kidneys clog renal tubules and damage them. Hypercalcemia also causes renal vasoconstriction and tubular damage. A — ANEMIA: Crowding of bone marrow by plasma cells reduces red blood cell production — causing fatigue, pallor, dyspnea. B — BONE LESIONS: Lytic (punched-out) lesions appear throughout the skeleton, especially the skull, spine, ribs, pelvis. These lesions weaken bones, causing BONE PAIN (especially BACK PAIN — most common presenting symptom) and PATHOLOGIC FRACTURES (fractures from minimal or no trauma). Bone pain is often the FIRST symptom. Additional manifestations: Recurrent Infections — myeloma cells produce abnormal, non-functional antibodies, and normal antibody production is suppressed. The patient cannot fight infections effectively (especially bacterial infections like pneumonia and sinusitis). Bence Jones Proteinuria — light chains in urine; detected by urine protein electrophoresis. Hyperviscosity syndrome — excess M protein makes blood thick and sluggish, causing visual changes, neurological symptoms, and mucosal bleeding. DIAGNOSIS: Serum protein electrophoresis (SPEP) showing M spike; Urine protein electrophoresis showing Bence Jones protein; Bone marrow biopsy showing >10% plasma cells (diagnostic criterion); Skeletal survey (X-rays) showing lytic lesions; Serum calcium (elevated), Creatinine (elevated), CBC (anemia). TREATMENT: Chemotherapy with novel agents: Bortezomib (proteasome inhibitor) and Lenalidomide (immunomodulator) are mainstays; Combined with Dexamethasone (a corticosteroid); AUTOLOGOUS STEM CELL TRANSPLANT — using the patient's own harvested stem cells after high-dose chemotherapy; Bisphosphonates (Zoledronic acid, Pamidronate) — prevent bone destruction, reduce fractures, treat hypercalcemia. Myeloma is NOT curable but is MANAGEABLE — median survival has improved significantly with modern treatment (5–7+ years). NURSING PRIORITIES: (1) HYDRATION — push 3–4 liters of fluid per day. This is CRITICAL: hydration dilutes M protein and calcium in the kidneys, flushing light chains before they damage renal tubules. It is the single most important nursing intervention; (2) MOBILITY — encourage ambulation. Weight-bearing activity slows bone breakdown (osteoclast activity) and reduces hypercalcemia; (3) Fracture Prevention — handle patients GENTLY during transfers and repositioning; avoid pulling on extremities; log-roll for position changes; (4) PAIN MANAGEMENT — bone pain is severe; administer analgesics as ordered; (5) Infection Prevention — these patients are severely immunocompromised; (6) Renal Monitoring — daily intake and output, creatinine trends.

Blood Transfusion: Administration and Reactions

Safe blood transfusion is one of the most critical nursing responsibilities under RA 9173, which mandates competent, evidence-based nursing practice. A transfusion error can kill a patient within minutes. PRE-TRANSFUSION PROCEDURE — the 'Two-Nurse Check' at the bedside: Verify PATIENT IDENTITY using TWO IDENTIFIERS (name and birthdate, or name and hospital ID number); Verify the BLOOD TYPE AND RH FACTOR matches the patient's type; Verify the CROSSMATCH/UNIT NUMBER on the blood bag matches the blood bank label; Verify the EXPIRATION DATE — blood must be used before the stated expiration; Inspect the BAG for leaks, unusual color, or turbidity (cloudiness). ANY discrepancy — STOP and do NOT transfuse until clarified. Obtain INFORMED CONSENT before elective transfusions. Obtain BASELINE VITAL SIGNS (temperature, pulse, blood pressure, respirations) BEFORE starting — a pre-existing fever may mask a febrile reaction; notify physician if temperature is already elevated. EQUIPMENT AND SOLUTIONS: Use a LARGE-BORE IV catheter (18–20 gauge) to allow RBCs to flow without damage; Use BLOOD ADMINISTRATION TUBING with an IN-LINE FILTER (Y-set); The ONLY IV solution compatible with blood is 0.9% NORMAL SALINE. NEVER infuse blood with: Dextrose solutions (D5W, D10W) — sugar causes RBC clumping and hemolysis; Lactated Ringer's solution — calcium in LR can trigger clotting in the blood bag; Any medications — always use a separate line. START INFUSION RATE: Begin at a SLOW RATE (approximately 2 mL/minute or 50 mL for the first 15 minutes); STAY WITH THE PATIENT for the FIRST 15 MINUTES — most severe reactions occur early; Re-check vital signs at 15 minutes; If no reaction, increase to prescribed rate. TIME LIMIT: Each unit must be transfused within 4 HOURS maximum — beyond this, bacterial growth in blood becomes a significant risk. If a unit cannot be completed in 4 hours, return it to the blood bank. TRANSFUSION REACTIONS — CRITICAL KNOWLEDGE: If ANY reaction is suspected: STOP THE TRANSFUSION IMMEDIATELY (disconnect the blood, NOT the IV line); Keep the vein open with NORMAL SALINE via NEW TUBING (do not use the same blood-contaminated tubing); Notify the PHYSICIAN and BLOOD BANK immediately; Monitor vital signs frequently; SAVE the blood bag and tubing and SEND THEM TO THE BLOOD BANK for testing; Send blood and urine samples for analysis. Specific Reaction Types: (1) ACUTE HEMOLYTIC REACTION — MOST DANGEROUS/MOST SEVERE; Cause: ABO INCOMPATIBILITY (wrong blood type given to patient — almost always a clerical/identification error); Timing: Onset within MINUTES; Manifestations: Fever, CHILLS, severe BACK/FLANK PAIN (from hemolysis), HYPOTENSION, tachycardia, dyspnea, HEMOGLOBINURIA (red-brown urine from lysed RBC hemoglobin in urine), and progression to shock, DIC, and acute renal failure; (2) FEBRILE NON-HEMOLYTIC REACTION — MOST COMMON reaction; Cause: Recipient antibodies react to DONOR LEUKOCYTES; Timing: During or shortly after transfusion; Manifestations: FEVER (rise of 1°C or more) and CHILLS without evidence of hemolysis; Prevention: Use LEUKOCYTE-REDUCED (leukopoor) blood products; Treatment: Antipyretics (acetaminophen); (3) MILD ALLERGIC REACTION; Cause: Plasma proteins in the donor blood; Manifestations: URTICARIA (hives) and ITCHING — localized; Treatment: ANTIHISTAMINES (diphenhydramine); transfusion may be RESUMED SLOWLY after symptoms resolve if mild; (4) ANAPHYLACTIC REACTION; Cause: IgA-DEFICIENT recipients who have anti-IgA antibodies — react to IgA in donor blood; Timing: After just a few milliliters; Manifestations: Bronchospasm, wheezing, hypotension, shock — SEVERE; Treatment: STOP transfusion, epinephrine, maintain airway; Future: Use washed blood products or IgA-deficient blood; (5) CIRCULATORY OVERLOAD (TACO = Transfusion-Associated Circulatory Overload); Cause: Too much volume transfused too quickly; High-risk patients: elderly, cardiac patients, small children; Manifestations: Dyspnea, CRACKLES (pulmonary edema), HYPERTENSION, distended neck veins, headache; Treatment: SLOW OR STOP infusion, sit patient UPRIGHT, administer DIURETICS (furosemide) and OXYGEN; Prevention: Transfuse slowly in high-risk patients; (6) TRALI (Transfusion-Related Acute Lung Injury); Cause: Donor antibodies activate recipient neutrophils in the lungs; Timing: Within 6 HOURS; Manifestations: Acute respiratory distress (dyspnea, hypoxia, bilateral infiltrates on X-ray) WITHOUT hypertension (differentiates from TACO); Treatment: Respiratory support (supplemental O2, mechanical ventilation if needed); (7) DELAYED HEMOLYTIC REACTION; Timing: Days to weeks AFTER transfusion; Due to alloantibodies not detected at crossmatch; (8) GRAFT-VERSUS-HOST DISEASE — in immunocompromised recipients; donor lymphocytes attack host tissues; prevent with IRRADIATED blood products.

Hemarthrosis (joint bleeding) is the hallmark complication of hemophilia. The treatment cascade follows: RICE first for immediate hemorrhage control, then factor replacement is the definitive therapy. The critical teaching point: aspirin and NSAIDs are absolutely contraindicated — they inhibit platelet function and will worsen bleeding. Acetaminophen is the only safe analgesic. Compartment syndrome monitoring is essential — increased bleeding in a closed compartment can compress nerves and vessels, leading to permanent damage. The nurse must also document the hemarthrosis episode so the physician can evaluate the need for prophylactic factor replacement to prevent future joint destruction (hemophilic arthropathy).

This problem tests two key skills: pre-transfusion assessment and reaction identification. The low-grade fever is important because an actual hemolytic reaction also causes fever — if the nurse starts transfusion with an existing fever, the hemolytic reaction may not be recognized early. For the reaction: TACO vs TRALI distinction is critical. Both cause respiratory distress, but TACO has HYPERTENSION (from fluid overload causing increased preload) while TRALI is associated with NORMAL or LOW blood pressure. TACO responds to diuretics; TRALI does not. Elderly patients with CHF are the classic TACO high-risk group. The management sequence (stop → upright → O2 → diuretics → notify) follows the ABCs framework.

This scenario represents advanced DIC in the context of the most common trigger: sepsis. The KEY learning point: treating DIC without treating the underlying cause is futile — the clotting cascade will continue to be activated as long as sepsis persists. Blood product replacement buys time but does not resolve DIC. The nurse must prioritize antibiotic administration and sepsis management alongside the bleeding management. The lab pattern is classic DIC: the ONLY condition where ALL five parameters are abnormal simultaneously (unlike hemophilia where only aPTT is prolonged, or ITP where only platelets are low). The bilateral assessment for both bleeding (oozing, petechiae, hematuria) and clotting (skin color, extremity perfusion, urine output) reflects the dual nature of DIC.

Multiple myeloma presents as a constellation of seemingly unrelated problems (back pain, kidney trouble, anemia, infections) that together reveal a unifying diagnosis. The nurse's role spans immediate safety (fracture and fall prevention), renal protection (hydration), symptom management (pain), and preparing for diagnostic workup. The COUNTERINTUITIVE key teaching: DO encourage mobility despite bone lesions. The instinct is to keep the patient at bed rest to 'protect' the bones, but immobility WORSENS hypercalcemia (calcium floods the bloodstream when weight-bearing activity stops). Supervised, careful ambulation is both safe and therapeutic. Bisphosphonates will be ordered to further protect bones — teach patients about slow IV infusion requirements and the rare complication of osteonecrosis of the jaw with bisphosphonate therapy.